List of Excipients in Branded Drug DEFINITY RT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	ACETIC ACID	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	GLYCERIN	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	PROPYLENE GLYCOL	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	SODIUM ACETATE ANHYDROUS	2037-05-04

DEFINITY RT Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

DEFINITY RT is Lantheus Holdings’ room-temperature-stable ultrasound contrast agent containing perflutren lipid microspheres. Its commercial differentiation is primarily formulation and supply-chain performance: reduced cold-chain dependence, longer operational flexibility, and improved hospital inventory management. The main excipient opportunities are in pharmaceutical-grade phospholipids, PEGylated lipids, vial and closure systems, stability testing, manufacturing controls, and regional supply arrangements.

What is DEFINITY RT and how does its formulation work?

DEFINITY RT is an injectable ultrasound-enhancing agent used in adults with suboptimal echocardiograms. The product contains microspheres filled with perflutren gas. After intravenous administration, the microspheres improve ultrasound signal and help visualize cardiac chambers and the left ventricular endocardial border. The product is activated before use with Lantheus’ Vialmix device. The active gas is not dissolved as a conventional small-molecule drug; it is contained within lipid-shell microspheres (U.S. Food and Drug Administration [FDA], 2024a).

The formulation depends on four functional elements:

Formulation element	Primary function	Commercial relevance
Perflutren gas	Ultrasound-scattering core	Defines the drug substance and acoustic performance
Phospholipid shell	Forms and stabilizes microspheres	Main excipient and raw-material control point
PEGylated phospholipid	Supports shell stability and circulation behavior	Potential source of composition and process IP
Aqueous buffer and tonicity agents	Maintains pH, osmolality and injectability	Lower-margin but essential for product quality
Vial and closure system	Preserves gas retention and sterility	Critical to shelf life and room-temperature stability

Public labeling for DEFINITY products identifies lipid components, including dipalmitoyl phosphatidylglycerol and a PEGylated phospholipid, together with aqueous formulation components. Exact formulation proportions and process parameters are proprietary and are not fully disclosed in the prescribing information (FDA, 2024a).

How does DEFINITY RT differ from conventional DEFINITY?

The strategic distinction is storage and handling rather than a new diagnostic target. Conventional DEFINITY has historically required refrigerated storage. DEFINITY RT was developed to permit room-temperature storage under labeled conditions, reducing the operational burden associated with refrigerated contrast media.

Attribute	Conventional DEFINITY	DEFINITY RT
Active component	Perflutren lipid microspheres	Perflutren lipid microspheres
Clinical use	Echocardiography and ultrasound imaging	Echocardiography and ultrasound imaging
Microsphere technology	Lipid-shell microspheres	Lipid-shell microspheres
Activation	Vialmix device	Vialmix device
Supply-chain profile	Refrigerated storage	Room-temperature storage under approved labeling
Commercial advantage	Established clinical adoption	Lower cold-chain cost and greater site flexibility
Main formulation challenge	Microsphere integrity during refrigerated storage	Maintaining integrity through broader temperature exposure

The room-temperature claim creates a demanding stability target. The manufacturer must demonstrate that microsphere concentration, size distribution, acoustic response, gas retention, sterility, particulate profile, and delivered dose remain within specifications during labeled storage and shipping.

What excipients protect the commercial value of DEFINITY RT?

The most important excipients are the phospholipid shell materials. They determine whether the product can maintain a stable population of microspheres during storage, activation, injection, and circulation.

Phospholipid selection

Phospholipids must meet pharmaceutical-grade standards for identity, purity, oxidation, hydrolysis, residual solvents, endotoxins, bioburden and particle contamination. Small changes in acyl-chain composition, headgroup chemistry, fatty-acid impurities or water content can affect:

• Microsphere formation
• Shell elasticity
• Gas retention
• Acoustic reflectivity
• Activation performance
• Stability after temperature excursions
• Aggregation and particle-size distribution

A supplier that can provide consistent lots of high-purity phospholipids with strong analytical characterization has a potentially valuable position in the DEFINITY RT supply chain.

PEGylated phospholipids

PEGylated phospholipids are strategically important because they affect interfacial behavior and may reduce aggregation of the microspheres. Their commercial value is higher than that of ordinary formulation buffers because they require more complex synthesis, purification and characterization.

Key control parameters include:

• PEG molecular-weight distribution
• Degree of substitution
• Positional isomer profile
• Residual free PEG
• Residual solvents and catalysts
• Phospholipid oxidation
• Hydrolysis products
• Batch-to-batch surface activity

A second-source manufacturer would need more than a compendial certificate. It would need equivalence data showing that a replacement lipid produces microspheres with comparable size, concentration, acoustic response and stability.

Buffer and tonicity system

The aqueous phase supports pH, osmolality and injection tolerability. These components are generally easier to source and less likely to create durable differentiation than the lipid shell. Their commercial importance rises when the formulation is sensitive to ionic strength, buffer capacity or interaction with the vial and closure.

The opportunity for suppliers is strongest in high-purity, low-endotoxin grades with validated supply continuity. Substitution risk is lower than for the phospholipids but still requires comparability and regulatory assessment.

What formulation patents may protect DEFINITY RT?

Protection for DEFINITY RT may arise from several claim categories:

1. Lipid-shell composition claims covering specific phospholipid combinations.
2. PEGylated lipid composition claims.
3. Microsphere size, concentration or acoustic-performance claims.
4. Room-temperature stability claims.
5. Manufacturing-process claims covering hydration, gas exchange, emulsification or activation.
6. Container-closure claims that preserve gas content and microsphere integrity.
7. Use claims covering echocardiographic imaging or specific patient populations.
8. Device claims covering activation with Vialmix or a compatible activation system.

The FDA label does not disclose the full patent estate. A definitive patent number, expiration-date and Orange Book analysis requires a current review of the FDA Orange Book, USPTO records, international patent databases and Lantheus’ regulatory filings. Public regulatory materials establish the product, indication and storage conditions, but they do not by themselves establish the complete scope of formulation, manufacturing or device protection.

What is the FDA regulatory status of DEFINITY RT?

DEFINITY RT is approved in the United States under Lantheus’ DEFINITY product family. The product is regulated as a prescription injectable drug and ultrasound contrast agent. The approved use is enhancement of echocardiographic imaging in adults when the endocardial border is not adequately visualized.

The regulatory burden is driven by the complexity of the microsphere system. FDA review is likely to focus on:

• Drug-product identity and strength
• Microsphere size distribution
• Perflutren content
• Lipid composition
• Sterility and endotoxin control
• Extractables and leachables
• Container-closure integrity
• Stability under labeled storage
• In-use stability after activation
• Device compatibility
• Comparative acoustic performance

Excipient changes are not automatically low-risk. A change in phospholipid source, PEGylated lipid grade, mixing energy, hydration temperature or vial material could alter the critical quality attributes of the final product.

When does DEFINITY RT lose exclusivity?

DEFINITY RT’s exclusivity analysis has two separate components: regulatory exclusivity and patent exclusivity.

The underlying DEFINITY product received FDA approval in 2001. DEFINITY RT represents a later formulation and product-development milestone, but the relevant regulatory exclusivity period depends on the specific FDA supplement or approval pathway used for the room-temperature formulation. A formulation approval does not automatically create the same exclusivity period as a new chemical entity.

Potential entry routes include:

• An abbreviated new drug application for a qualifying generic product
• A 505(b)(2) application relying partly on DEFINITY data
• A product using the same active ingredient but a different microsphere formulation
• A competing ultrasound contrast agent using a different gas or shell technology
• A device-enabled product with a distinct activation and delivery system

Because perflutren lipid microspheres are complex drug products, a copycat product may face technical comparability barriers even if the active gas is identical.

How many patents cover DEFINITY RT and what is the Orange Book status?

The number of enforceable patents cannot be stated reliably without a current, record-level patent search. The relevant analysis must distinguish among:

• Patents listed in the FDA Orange Book
• Unlisted formulation patents
• Process patents
• Device patents
• Patents assigned to Lantheus or related entities
• Expired foundational patents
• Continuations and divisionals
• Foreign rights with different expiration dates

The Orange Book is the principal source for patents that may be relevant to an ANDA Paragraph IV certification. The absence of an Orange Book listing would not eliminate risk from non-listed patents, trade secrets or regulatory exclusivity. Conversely, a listed patent does not prove that the patent would survive validity or infringement challenges (FDA, 2024b).

Which companies are challenging DEFINITY RT?

No specific DEFINITY RT Paragraph IV challenger or publicly identified settlement agreement is established in the sources cited here. The competitive risk is more likely to arise first from other ultrasound contrast agents and from development-stage microsphere technologies than from a simple conventional generic.

The key competitor groups are:

Competitor group	Risk to DEFINITY RT	Main differentiation
Existing ultrasound contrast agents	High in hospital formularies	Clinical familiarity, workflow and contracting
Generic or 505(b)(2) perflutren products	Moderate	Price and supply
Lipid-microsphere platforms using other gases	Moderate	Imaging performance and storage profile
Targeted or molecular ultrasound agents	Longer-term	Disease-specific imaging applications
Non-contrast ultrasound technologies	Selective	Workflow and avoidance of injectable agents

Biosimilar risk is not applicable in the conventional sense because DEFINITY RT is not a biologic therapeutic. The relevant issue is complex drug-product substitution, not biosimilar interchangeability. FDA may require substantial pharmaceutical and performance comparability before a competing product can obtain approval.

What manufacturing and excipient barriers limit generic entry?

The most important barriers are process-related rather than simple ingredient availability.

Manufacturing barriers

A developer would need to control:

• Lipid hydration and dispersion
• Microsphere generation
• Gas loading
• Mixing and shear conditions
• Particle-size distribution
• Free-lipid removal
• Vial filling
• Headspace composition
• Container-closure integrity
• Activation reproducibility

The same nominal excipient composition can produce different clinical and acoustic performance if the manufacturing process changes. This creates a high risk that a generic sponsor will need extensive development work even where the active gas and listed excipients are known.

Analytical barriers

Routine chemical assays are insufficient. A robust analytical package would likely include:

• Dynamic light scattering or equivalent particle-sizing methods
• Coulter-counter or optical particle analysis
• Microscopy
• Gas-content testing
• Acoustic backscatter testing
• In-use stability
• Vialmix activation studies
• Temperature-excursion studies
• Extractables and leachables evaluation

Analytical methods that correlate formulation attributes with image quality can create valuable know-how and licensing opportunities.

What commercial opportunities exist for excipient suppliers?

Qualified second-source phospholipids

The strongest near-term opportunity is a qualified second source for the principal phospholipid and PEGylated phospholipid components. Lantheus or a contract manufacturer would value supply redundancy if the supplier can match the incumbent material’s critical attributes.

Commercial requirements include:

• DMF support
• GMP manufacturing
• Multi-lot comparability
• Long-term stability data
• Oxidation-control strategy
• Global regulatory documentation
• Capacity commitments
• Change-control transparency

Specialized lipid manufacturing

A supplier with integrated synthesis, purification and analytical testing can capture more value than a commodity distributor. The opportunity is strongest for PEGylated phospholipids with narrow molecular-weight distribution and low impurity profiles.

Container-closure systems

DEFINITY RT places value on vials, stoppers, seals and packaging that maintain gas retention and protect the microsphere suspension during room-temperature storage. Opportunities include:

• Low-permeability elastomers
• Reduced extractables stoppers
• Improved crimp-seal systems
• Temperature-indicator packaging
• Validated shipping configurations
• Vial systems compatible with Vialmix

Contract development and manufacturing

CDMOs with sterile lipid formulation, microsphere processing and aseptic filling capabilities may pursue development or regional manufacturing agreements. The best-positioned CDMOs will have experience with sterile suspensions rather than only conventional small-molecule liquids.

Regional licensing

Room-temperature stability has particular value in markets with inconsistent cold-chain infrastructure. Licensing or distribution arrangements could focus on Latin America, Southeast Asia, the Middle East and selected European markets, subject to local approval and supply economics.

How strong is the DEFINITY RT patent estate?

The patent estate should be assessed as a layered formulation-and-process portfolio rather than as a single active-ingredient patent. Foundational protection around perflutren and lipid microspheres is likely to be older than the room-temperature formulation. The commercial strength therefore depends on whether later patents cover a necessary formulation composition or merely optional process conditions.

A strong estate would have claims that:

• Require a specific lipid combination
• Define a measurable stability threshold
• Cover the approved room-temperature storage range
• Connect the formulation to a defined microsphere population
• Cover essential activation or filling parameters
• Have surviving claims with enforceable scope

A weaker estate would rely primarily on broad, expired or easily designed-around claims. Trade secrets may remain important where the patent record does not disclose the precise manufacturing conditions.

What revenue exposure does DEFINITY RT create for Lantheus?

DEFINITY is a core Lantheus product and an established ultrasound contrast franchise. DEFINITY RT can extend the franchise commercially by improving storage, inventory and workflow economics rather than by creating a new indication.

Potential revenue benefits include:

• Greater use in outpatient imaging centers
• Lower product loss from refrigerated inventory expiration
• Broader hospital stocking
• Reduced distribution complexity
• Better access in markets with limited cold-chain infrastructure
• Premium pricing for handling convenience
• Protection of the DEFINITY franchise against formulation-based competitors

The main downside is cannibalization of conventional DEFINITY sales if customers migrate without materially expanding utilization. Pricing strategy will determine whether the room-temperature formulation produces volume growth, margin expansion or both.

What generic launch scenarios exist for DEFINITY RT?

Early launch through a non-infringing formulation

A competitor could pursue a different lipid ratio, shell composition or storage approach. This route may avoid some formulation claims but would increase development and clinical-performance risk.

Paragraph IV challenge

A generic sponsor could certify that listed patents are invalid, unenforceable or not infringed. The sponsor would then face potential Hatch-Waxman litigation and a possible 30-month stay of approval if the patent holder files suit within the statutory period (FDA, 2023).

505(b)(2) product

A 505(b)(2) applicant could rely on existing safety and efficacy information while conducting bridging studies for a modified microsphere formulation. This approach may be more suitable than an ANDA if the formulation, activation process or device differs materially.

Non-perflutren competitor

A different ultrasound gas or shell technology could avoid direct DEFINITY patent claims. The entrant would compete on image quality, safety, storage, activation and price rather than on pharmaceutical equivalence.

Key Takeaways

• DEFINITY RT’s core value is room-temperature stability for a perflutren lipid-microsphere product.
• Phospholipids and PEGylated phospholipids are the highest-value excipient categories.
• Excipient substitution requires final-product comparability because shell chemistry directly affects microsphere performance.
• The principal commercial opportunities are qualified lipid suppliers, sterile microsphere CDMOs, container-closure providers and regional distributors.
• Generic entry is technically difficult because manufacturing conditions influence particle size, gas retention and acoustic performance.
• DEFINITY RT is not exposed to conventional biosimilar substitution; its relevant competitive threat is complex-drug-product replication.
• A complete patent conclusion requires current Orange Book and patent-database records. The strongest likely protection would be formulation, stability, process and device claims rather than the mature perflutren active ingredient alone.

FAQs

Can ordinary pharmaceutical-grade phospholipids replace DEFINITY RT excipients?

Not without development and regulatory comparability work. Purity, oxidation, hydrolysis, PEG distribution and interfacial properties can change microsphere performance even when the excipient name is identical.

Does room-temperature storage eliminate DEFINITY RT cold-chain costs entirely?

It can reduce refrigerated distribution and inventory requirements under the approved label, but controlled shipping, temperature monitoring and storage-condition qualification remain necessary.

Could a lipid supplier obtain patent protection around a DEFINITY RT excipient?

Yes. Patentable subject matter could include a novel lipid composition, impurity profile, manufacturing process, stabilized excipient blend or microsphere formulation, provided the statutory novelty and inventive-step requirements are met.

Is Vialmix part of the DEFINITY RT drug product?

Vialmix is the activation device used with DEFINITY products. Its compatibility and activation performance are important to the overall product system, even though the device and injectable suspension may have separate regulatory and intellectual-property rights.

What is the most attractive commercial entry point for a new supplier?

A qualified second source for the PEGylated phospholipid or principal shell lipid is the most attractive entry point. Container-closure systems and specialized sterile microsphere manufacturing are the next strongest opportunities.

References

1. U.S. Food and Drug Administration. (2023). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
2. U.S. Food and Drug Administration. (2024a). DEFINITY RT (perflutren lipid microsphere) injectable suspension: Prescribing information.
3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. Lantheus Holdings, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.